The Need for United States–Based Guidelines for Myeloproliferative Neoplasms

Authors: Brady L. Stein MD, MHS, Susan O’Brien MD, Peter Greenberg MD and Ruben A. Mesa MD
View More View Less
Restricted access

Brady L. Stein, MD, MHS, received Internal Medicine training and fellowship training in hematology from the Johns Hopkins University School of Medicine. During fellowship, he was an awardee of the K12 Blood Scholars Program, focusing on clinical research in hematology. During that program, he received an MHS in Clinical Investigwation at the Johns Hopkins Bloomberg School of Public Health. He moved to Northwestern University Feinberg School of Medicine in the summer of 2010 as an Attending Physician in Hematology/Oncology.

Susan O’Brien, MD, is Associate Director for Clinical Science for the Chao Family Comprehensive Cancer Center and Medical Director of the Sue and Ralph Stern Center for Cancer Clinical Trials and Research at UC Irvine Health, Irvine, California and former Chair of the NCCN Guidelines for chronic myelogenous leukemia.

The ideas and viewpoints expressed in this commentary are those of the author and do not necessarily represent any policy, position, or program of NCCN.

Peter Greenberg, MD, is Professor of Medicine, Hematology Division, at Stanford Cancer Institute, and Chair of the NCCN Guidelines Panel for Myelodysplastic Syndromes.

Ruben A. Mesa, MD, is Professor of Medicine of Mayo Medical School and chair of the Division of Hematology/Oncology in the Department of Internal Medicine at Mayo Clinic and deputy director at Mayo Clinic Cancer Center in Arizona. Dr. Mesa is active in the Arizona Cancer Coalition. Dr. Mesa attended University of Illinois at Urbana-Champaign for his undergraduate degree and earned his medical degree at Mayo Medical School. He completed both a residency in internal medicine and a fellowship in hematology/medical oncology at Mayo Graduate School of Medicine.

  • 1.

    Stein BL, Gotlib J, Arcasoy M. Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms. J Natl Compr Canc Netw 2015;13:424434.

    • Search Google Scholar
    • Export Citation
  • 2.

    Bench AJ, White HE, Foroni L. Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations. Br J Haematol 2013;160:2534.

    • Search Google Scholar
    • Export Citation
  • 3.

    Reilly JT, McMullin MF, Beer PA. Guideline for the diagnosis and management of myelofibrosis. Br J Haematol 2012;158:453471.

  • 4.

    Harrison CN, Bareford D, Butt N. Guideline for investigation and management of adults and children presenting with a thrombocytosis. Br J Haematol 2010;149:352375.

    • Search Google Scholar
    • Export Citation
  • 5.

    McMullin MF, Reilly JT, Campbell P. Amendment to the guideline for diagnosis and investigation of polycythaemia/erythrocytosis. Br J Haematol 2007;138:821822.

    • Search Google Scholar
    • Export Citation
  • 6.

    Tefferi A, Cervantes F, Mesa R. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood 2013;122:13951398.

    • Search Google Scholar
    • Export Citation
  • 7.

    Barosi G, Mesa R, Finazzi G. Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood 2013;121:47784781.

    • Search Google Scholar
    • Export Citation
  • 8.

    Barbui T, Barosi G, Birgegard G. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 2011;29:761770.

    • Search Google Scholar
    • Export Citation
  • 9.

    Greenberg PL, Attar E, Bennett JM. Myelodysplastic syndromes: clinical practice guidelines in oncology. J Natl Compr Canc Netw 2013;11:838874.

    • Search Google Scholar
    • Export Citation
  • 10.

    O’Brien S, Radich JP, Abboud CN. Chronic Myelogenous Leukemia, Version 1.2014. J Natl Compr Canc Netw 2013;11:13271340.

  • 11.

    Akin C. Molecular diagnosis of mast cell disorders: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology. J Mol Diagn 2006;8:412419.

    • Search Google Scholar
    • Export Citation
  • 12.

    Maxson JE, Gotlib J, Pollyea DA. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. N Engl J Med 2013;368:17811790.

    • Search Google Scholar
    • Export Citation
  • 13.

    Piazza R, Valletta S, Winkelmann N. Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet 2013;45:1824.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 75 39 2
PDF Downloads 18 13 1
EPUB Downloads 0 0 0